Pardal Joana, Sundram Uma, Selim M Angelica, Hoang Mai P
*Departments of Pathology, Porto Medical School and Sao Joao Hospital, Porto, Portugal; †Departments of Pathology, William Beaumont School of Medicine, Royal Oak, MI; ‡Departments of Pathology, Duke University Medical Center, Durham, NC; and §Departments of Pathology, Harvard Medical School and Massachusetts General Hospital, Boston, MA.
Am J Dermatopathol. 2017 Apr;39(4):279-286. doi: 10.1097/DAD.0000000000000634.
Knowledge of staining pattern of certain immunostains might be useful in the classification of cutaneous adnexal tumors that can have clinical importance. We studied GATA3 and MYB expression in archival materials of 220 adnexal tumors comprised of sebaceous carcinomas, follicular tumors, apocrine carcinoma, predominantly apocrine tumors, predominantly eccrine tumors, and others including adenoid cystic carcinomas. Nuclear GATA3 expression was seen in 70% (153/220) of cases, including sebaceous carcinoma (93%), apocrine carcinoma (93%), follicular neoplasms (100%), and predominantly apocrine neoplasms (69%), yet only 38% of predominantly eccrine neoplasms. Nuclear MYB expression was seen in 43% (81/188) of cases, including adenoid cystic carcinoma (90%), predominantly apocrine tumors (66%), follicular neoplasms (49%), apocrine carcinomas (14%), predominantly eccrine tumors (11%), and sebaceous carcinomas (4%). GATA3 and MYB expression were noted in 43% (9/21) and 24% (5/21) of cutaneous metastases, respectively. Expression of both GATA3 and MYB was noted in 33% (60/184) of primary adnexal tumors versus 19% (4/21) of cutaneous metastases. GATA3 preferentially labels tumors with follicular, sebaceous, and apocrine differentiation. MYB is potentially a helpful stain in the distinction of desmoplastic trichoepithelioma versus basal cell carcinoma. The coexpression of GATA3 and MYB might be helpful in the distinction of primary cutaneous adnexal carcinoma versus metastatic breast, salivary gland, or urothelial carcinoma.
了解某些免疫染色的染色模式可能有助于对具有临床重要性的皮肤附属器肿瘤进行分类。我们研究了220例附属器肿瘤存档材料中GATA3和MYB的表达情况，这些肿瘤包括皮脂腺癌、毛囊肿瘤、大汗腺癌、以大汗腺为主的肿瘤、以小汗腺为主的肿瘤以及其他肿瘤（包括腺样囊性癌）。70%（153/220）的病例可见核GATA3表达，包括皮脂腺癌（93%）、大汗腺癌（93%）、毛囊肿瘤（100%）以及以大汗腺为主的肿瘤（69%），而以小汗腺为主的肿瘤中仅有38%有核GATA3表达。43%（81/188）的病例可见核MYB表达，包括腺样囊性癌（90%）、以大汗腺为主的肿瘤（66%）、毛囊肿瘤（49%）、大汗腺癌（14%）、以小汗腺为主的肿瘤（11%）以及皮脂腺癌（4%）。皮肤转移瘤中GATA3和MYB表达分别见于43%（9/21）和24%（5/21）。原发性附属器肿瘤中33%（60/184）同时表达GATA3和MYB，而皮肤转移瘤中这一比例为19%（4/21）。GATA3优先标记具有毛囊、皮脂腺和大汗腺分化的肿瘤。MYB可能有助于鉴别促结缔组织增生性毛发上皮瘤和基底细胞癌。GATA3和MYB的共表达可能有助于鉴别原发性皮肤附属器癌与转移性乳腺癌、唾液腺癌或尿路上皮癌。
